Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease
Status:
Completed
Trial end date:
2017-05-19
Target enrollment:
Participant gender:
Summary
Our primary objective is to assess whether inhaling vaporized cannabis ameliorates chronic
pain in patients with sickle cell disease (SCD). As these patients will all be on chronic
opioid analgesics, the investigators will also assess the possible synergistic affect between
inhaled cannabis and opioids. The investigators will also assess the clinical safety of the
concomitant use of cannabinoids and these opioids in patients with SCD by monitoring the
short-term side effects associated with combined therapy. Finally, the investigators will
evaluate the short-term effects of inhaled cannabis on markers of inflammation and disease
progression in patients with SCD.
Hypotheses are as follows:
1. Inhaled cannabis will significantly reduce chronic pain in patients with SCD.
2. Inhaled cannabis will significantly alter the short-term side effects experienced by
patients who take opioids for SCD.
3. Inhaled cannabis will significantly alter markers of inflammation and disease
progression in patients with SCD compared to placebo.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) University of Minnesota University of Minnesota - Clinical and Translational Science Institute